- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Wall Street Wire: StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data | 473 | Newsfile | New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco... ► Artikel lesen | |
| NUVECTIS PHARMA Aktie jetzt für 0€ handeln | |||||
| 08.07. | Wall Street Analysts See a 61.46% Upside in Nuvectis Pharma (NVCT): Can the Stock Really Move This High? | 2 | Zacks | ||
| 30.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 30.06. | Kapitalerhöhung mit hohem Abschlag: Nuvectis Pharma Aktie bricht um 25 % ein | 3 | Investing.com Deutsch | ||
| 30.06. | Nuvectis Pharma shares slide 19% on pricing of $100M stock offering | 1 | Seeking Alpha | ||
| 30.06. | Nuvectis Pharma prices $100 million public offering at $20/share | 3 | Investing.com | ||
| 30.06. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock | 2 | GlobeNewswire (USA) | ||
| 29.06. | Nuvectis Pharma announces public share offering to support drug programs | 1 | Seeking Alpha | ||
| 29.06. | Nuvectis Pharma, Inc.: Nuvectis Pharma Announces Proposed Public Offering of Common Stock | 1 | GlobeNewswire (USA) | ||
| 26.06. | What Makes Nuvectis Pharma (NVCT) a New Buy Stock | 1 | Zacks | ||
| 24.06. | Haisco and Nuvectis sign licensing deal for two drugs | 3 | Pharmaceutical Technology | ||
| 23.06. | Haisco lizenziert Wirkstoffkandidaten an Nuvectis - 40 Millionen US-Dollar Sofortzahlung | 14 | Investing.com Deutsch | ||
| 23.06. | Haisco licenses two drug candidates to Nuvectis for $40m upfront | 1 | Investing.com | ||
| 23.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.06. | China's Haisco Soars After Granting Nuvectis Rights to Two Innovative Drugs in Up to USD1.4 Billion Deal | 1 | Yicai Global | ||
| 23.06. | Nuvectis Pharma Jumps 20% To 52-Week High - Here's Why NVCT Stock Is Trending | 2 | Benzinga.com | ||
| 22.06. | Nuvectis licenses two clinical-stage drugs from Haisco | 4 | Investing.com | ||
| 22.06. | Nuvectis Pharma, Inc.: Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds | 316 | GlobeNewswire (Europe) | The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor... ► Artikel lesen | |
| 12.06. | Nuvectis Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.05. | Wall Street Analysts Think Nuvectis Pharma (NVCT) Could Surge 57%: Read This Before Placing a Bet | 1 | Zacks |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,130 | -0,97 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 9,000 | +6,19 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,186 | -1,33 % | Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa | Cumulative sales milestones up to $255 million and modest upfront/near-term development milestonesRoyalties equaling 22% of net salesOcugen to manufacture and supply OCU400 MALVERN, Pa., July 13,... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,294 | -9,54 % | NurExone-Tochter Exo-Top nimmt mexikanischen Exosomenmarkt ins Visier | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,253 | -4,17 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| REDHILL BIOPHARMA | 0,705 | -3,56 % | RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation | The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to opaganib1 for the treatment of neuroblastoma, a type of cancer most... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,385 | -1,28 % | Onco-Innovations Limited: Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API | VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") announces the successful completion of its... ► Artikel lesen | |
| NOVOCURE | 13,385 | -6,72 % | JPMorgan nimmt NovoCure-Bewertung mit "Neutral" wieder auf | ||
| REVOLUTION MEDICINES | 163,45 | +4,37 % | Revolution Medicines: Nach Bauchspeicheldrüsenkrebs-Durchbruch - geht jetzt alles ganz schnell? | Eine Revolution im wahrsten Sinne des Unternehmensnamens: Die Biotech-Gesellschaft Revolution Medicines kann einen Paradigmenwechsel zur Behandlung von Bauchspeicheldrüsenkrebs einleiten. Die Datenlage... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,050 | 0,00 % | Citizens reiterates Ocular Therapeutix stock rating on Dextenza sales | ||
| ROCKET PHARMACEUTICALS | 3,020 | +1,00 % | ROCKET PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| PALISADE BIO | 1,965 | +3,97 % | Palisade Bio, Inc.: Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis | ASCENTRA-UC expected to enroll up to 204 patients with moderately to severely active ulcerative colitis across North America and Europe First patient enrollment anticipated in the second half of 2026... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,850 | -3,75 % | Oncolytics Biotech, Inc.: Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial | Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential... ► Artikel lesen | |
| OUTLOOK THERAPEUTICS | 1,220 | -4,01 % | Outlook Therapeutics, Inc. - 8-K, Current Report | ||
| OMEROS | 8,260 | +2,48 % | Omeros (OMER) is Amongst The Best Names Under $10 That Could Yield More Than 200% Return |
NUVECTIS PHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 19,140 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NUVECTIS PHARMA INC finden Sie auf Wallstreet Online.